These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29634142)

  • 41. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
    Bjerklund Johansen TE; Baker TM; Black LK
    BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
    Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
    Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
    Oelke M; Roehrborn CG; D'Ancona C; Wilson TH; Castro R; Manyak M
    World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.
    Favilla V; Russo GI; Privitera S; Castelli T; Giardina R; Calogero AE; Condorelli RA; La Vignera S; Cimino S; Morgia G
    Aging Male; 2016 Sep; 19(3):175-181. PubMed ID: 27310433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
    Nizov AN
    Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
    Zabkowski T; Saracyn M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Combination therapy in the management of urinary disorders after transurethral resection of the prostate].
    Ergakov DV; Martov AG
    Urologiia; 2018 Mar; (1):62-70. PubMed ID: 29634136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
    Sountoulides P; Gravas S
    Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
    Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
    Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland.
    Ząbkowski T
    Pharmacol Rep; 2014 Aug; 66(4):565-9. PubMed ID: 24948055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
    Montorsi F; Roehrborn C; Garcia-Penit J; Borre M; Roeleveld TA; Alimi JC; Gagnier P; Wilson TH
    BJU Int; 2011 May; 107(9):1426-31. PubMed ID: 21348912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.